SEC Comment Letter 0000000000-23-008372 to Sonnet BioTherapeutics Holdings, Inc. (SONN) (CIK 0001106838)
Sonnet BioTherapeutics Holdings, Inc. (SONN) (CIK 0001106838)
Date: Aug. 3, 2023 · CIK: 0001106838 · Accession: 0000000000-23-008372
AI Filing Summary & Sentiment
File numbers found in text: 333-273516
Letter
United States securities and exchange commission logo August 3, 2023 Pankaj Mohan, Ph.D. Chief Executive Officer and Chairman Sonnet BioTherapeutics Holdings, Inc. 100 Overlook Center, Suite 102 Princeton, New Jersey 08540 Re:Sonnet BioTherapeutics Holdings, Inc. Registration Statement on Form S-1 Filed July 28, 2023 File No. 333-273516 Dear Pankaj Mohan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alexander E. Dinur, Esq.
Show Raw Text
United States securities and exchange commission logo
August 3, 2023
Pankaj Mohan, Ph.D.
Chief Executive Officer and Chairman
Sonnet BioTherapeutics Holdings, Inc.
100 Overlook Center, Suite 102
Princeton, New Jersey 08540
Re:Sonnet BioTherapeutics Holdings, Inc.
Registration Statement on Form S-1
Filed July 28, 2023
File No. 333-273516
Dear Pankaj Mohan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alexander E. Dinur, Esq.